Chen, X.; Hirt-Burri, N.; Scaletta, C.; Laurent, A.E.; Applegate, L.A.
Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts. Pharmaceutics 2025, 17, 692.
https://doi.org/10.3390/pharmaceutics17060692
AMA Style
Chen X, Hirt-Burri N, Scaletta C, Laurent AE, Applegate LA.
Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts. Pharmaceutics. 2025; 17(6):692.
https://doi.org/10.3390/pharmaceutics17060692
Chicago/Turabian Style
Chen, Xi, Nathalie Hirt-Burri, Corinne Scaletta, Alexis E. Laurent, and Lee Ann Applegate.
2025. "Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts" Pharmaceutics 17, no. 6: 692.
https://doi.org/10.3390/pharmaceutics17060692
APA Style
Chen, X., Hirt-Burri, N., Scaletta, C., Laurent, A. E., & Applegate, L. A.
(2025). Bicomponent Cutaneous Cell Therapy for Early Burn Care: Manufacturing Homogeneity and Epidermis-Structuring Functions of Clinical Grade FE002-SK2 Allogeneic Dermal Progenitor Fibroblasts. Pharmaceutics, 17(6), 692.
https://doi.org/10.3390/pharmaceutics17060692